Skip to main content
Voyageur Pharmaceuticals Ltd. logo

Voyageur Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · VM ISIN · CA92918C1014 TSXV Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2024-04-26 Interim / Quarterly Rep…
Country CA Canada
Listing TSXV VM

About Voyageur Pharmaceuticals Ltd.

https://voyageurpharmaceuticals.ca/

Voyageur Pharmaceuticals Ltd. develops and supplies contrast media products for medical imaging, including CT scans and fluoroscopy. The company operates using a vertically integrated "Earth to Bottle" strategy, controlling the entire supply chain from raw mineral acquisition to finished pharmaceutical product. Voyageur owns a significant, high-purity barium sulfate resource, positioning it as a secure and sustainable supplier of pharmaceutical-grade barium sulfate, the active ingredient in its commercialized contrast agents (e.g., SmoothX® and SmoothHD® series). This vertical control aims to ensure supply security and cost competitiveness, primarily targeting the North American market. The company is also actively developing iodine-based contrast media and V-Gas® Effervescent Granules to expand its portfolio of diagnostic imaging solutions.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Consolidated Financial Statements for the three months ended February 29, 2024 and February 28, 2023' and contains detailed unaudited interim financial statements including statements of financial position, comprehensive loss, changes in equity, and cash flows. It also includes notes to the condensed consolidated financial statements. The period covered is a quarter (three months), and the document explicitly states it is unaudited and interim. This matches the definition of an Interim / Quarterly Report (IR), which must contain actual financial statements and substantive financial data for a period shorter than a full fiscal year. The document is not a full annual report (10-K), nor is it an announcement or certification. It is a comprehensive financial report for a quarter, thus best classified as IR. Q1 2024
2024-04-26 English
News release - English.pdf
Director's Dealing Classification · 95% confidence The document is a press release announcing the issuance of Deferred Share Units (DSUs) to independent directors as part of an equity incentive compensation plan. It details the number of DSUs granted, their valuation, and the terms under which they are issued. There is no financial report, earnings data, or detailed management discussion. The content focuses on a compensation-related announcement to shareholders and the market. This fits best under the category of Director's Dealing (DIRS), which covers reports of personal share transactions or equity compensation granted to directors and executives. The document is not a full financial report, regulatory filing, or other categories such as capital updates or governance information. Therefore, the classification is DIRS with high confidence.
2024-04-03 English
News release - English.pdf
Report Publication Announcement Classification · 95% confidence The document announces that Voyageur Pharmaceuticals has filed its annual audited financial statements and management's discussion and analysis for the year ended November 30, 2023. It also announces a stock option grant to directors, officers, and consultants. The document is a press release-style announcement rather than the full annual report itself. The length is 6256 characters, which is relatively short for a full annual report but consistent with an announcement. The key phrase is 'Voyageur Pharmaceuticals Ltd. announces that it has filed its annual audited financial statements and management's discussion and analysis... on SEDAR+.' This indicates the document is an announcement of the filing/publication of the annual report, not the report itself. Therefore, according to the MENU VS MEAL RULE, this is a Report Publication Announcement (RPA). The stock option grant is a secondary announcement but does not change the primary classification. Confidence is high due to clear wording and document length.
2024-03-26 English
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification statement by the CFO of Voyageur Pharmaceuticals Ltd. regarding the review and fair presentation of the company's annual filings for the financial year ended November 30, 2023. It references the annual filings including the AIF, annual financial statements, and annual MD&A, but does not contain any actual financial data or detailed report content itself. The document is a formal attestation or certification as per National Instrument 52-109 for venture issuers. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than the actual annual report or financial statements. The document length is short (3085 characters) and it is clearly a certification letter, not the report itself.
2024-03-26 English
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate signed by the CEO. It certifies the review and fair presentation of annual filings including the AIF, annual financial statements, and MD&A for the financial year ended November 30, 2023. The document is primarily an officer certification letter and does not contain actual financial data or the full annual report itself. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than the actual Annual Report (10-K) or Management Discussion & Analysis (MDA). The document length is short (3143 characters), consistent with a certification letter rather than a full report.
2024-03-26 English
Annual MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled 'Management’s Discussion & Analysis for the Year Ended November 30, 2023' and contains detailed analysis of the company's financial position, operational performance, financing activities, and strategic outlook for the fiscal year ended November 30, 2023. It references audited annual consolidated financial statements prepared under IFRS and discusses comprehensive loss, working capital, financing through private placements, and forward-looking statements. The content is consistent with a Management Discussion and Analysis (MD&A) report, which is a detailed explanation of financial results, business trends, and outlook, typically accompanying annual or interim financial statements. It is not the full annual report (10-K), nor is it a brief earnings release or a regulatory announcement. Therefore, the appropriate classification is Management Reports (MDA).
2024-03-26 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.